Fleck’s trademark phrase for his system at Western Michigan. Well, it is, but that’s not what it means here. The answer, which is a phrase that college football fans need to get used to, is the phrase “Row the Boat.” You might wonder how a team that went 8-5 (and 6-2 in the MAC) in each of the last two seasons gets all the way up to No.
#Broncos big mac deal 2016 mac#
“I don’t need to make $19 million a year,” Baum said, referring to the big pay package Bresch took home last year. “Tonight when I go home I’m going to eat a nice piece of fish and the fish I eat isn’t any better or worse than what she is going to eat.2015 record: 8-5 overall, 6-2 MAC (defeated Middle Tennessee 45-31 in the Bahamas Bowl) 1 Burning Question: How Far can Western Michigan Row the Boat?
“It would be CEO malpractice if she didn’t,” he said.īut Baum said he would not have raised the price as much. Given Mylan’s near-monopoly in the EpiPen space, Baum explained that Bresch would have been fired had she not raised prices. He applauded her for being “honest” about serious problems in the opaque pharmaceutical supply chain that encourage higher prices. The Imprimis CEO offered a mixed take on Bresch, the controversial Mylan boss. “We understand how the drug works and can make it effectively and affordably,” he said. In 2012, a meningitis outbreak caused by a Massachusetts compounding pharmacy led to the deaths of 64 people.īaum insists that Imprimis focuses on quality and has a deep understanding of epinephrine. By comparison, Mylan is a $23 billion giant with a workforce of nearly 35,000.Ĭompounded drugs may be a tougher sell because of safety concerns. Baum’s $52 million company is located in a modest office park in the outskirts of San Diego and has just 112 employees. Baum thinks this process can easily be replicated with EpiPen.Īnother factor is that tiny Imprimis doesn’t have nearly the same costs that big drug companies do. So how does it work? As a compounder, Imprimis takes items already approved by the FDA and repackages them to create the drug. Today, Imprimis has captured 20 percent of the market for this critical AIDS drug, producing more than 17,000 doses of its alternative, Baum said. Last year, the company launched a $1 alternative to Daraprim, the AIDS drug that overnight saw an incredible 5,000 percent price increase from the company led by the infamous Martin Shkreli. Imprimis has already had success in taking on expensive branded drugs with cheaper compounds. “We don’t have the desire to charge the public even $300, for something that costs so little,” Baum said. “That’s not how I want to live my life.” He believes he can make a customizable version of EpiPen and sell it profitably for less than $100, without gouging the public. The auto injector is available for between $3 and $7. “The cost of epinephrine is literally less than a Big Mac,” he said of EpiPen’s main ingredient. He pointed that one milligram of epinephrine, which is three times more than what’s needed in an EpiPen, costs just a few bucks. In response to the outcry, Mylan took the unusual step of announcing a fast-track launch of its own $300 generic EpiPen.īut Baum said his version of EpiPen would cost very little to make.
The drugmaker and its CEO Heather Bresch have become the newest faces of corporate greed.
The plans come amid the latest price gouging scandal over the 400 percent increase in EpiPen prices by Mylan. The company hopes to have it ready by the end of the year.
NEW YORK - Mark Baum believes the relentless EpiPen price hikes are “shameful” and his company is plotting a $100 alternative for the lifesaving allergy treatment.īaum, known for offering a $1 substitute for the $750 AIDS drug Daraprim, said Tuesday that his company Imprimis Pharmaceuticals has been quietly working on a compounded version of EpiPen for months. Please look at the time stamp on the story to see when it was last updated. This is an archived article and the information in the article may be outdated.
0 kommentar(er)
